Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy
Ramin Raoufinia,Hamid reza Rahimi,Neda Keyhanvar,Meysam Moghbeli,Nima Abdyazdani,Mehdi Rostami,Karim Naghipoor,Fatemeh Forouzanfar,Sara Foroudi,Ehsan Saburi
DOI: https://doi.org/10.1007/s12015-024-10697-4
2024-03-03
Stem Cell Reviews and Reports
Abstract:Epidermolysis bullosa (EB) is a rare genetic dermatosis characterized by skin fragility and blister formation. With a wide phenotypic spectrum and potential extracutaneous manifestations, EB poses significant morbidity and mortality risks. Currently classified into four main subtypes based on the level of skin cleavage, EB is caused by genetic mutations affecting proteins crucial for maintaining skin integrity. The management of EB primarily focuses on preventing complications and treating symptoms through wound care, pain management, and other supportive measures. However, recent advancements in the fields of stem cell therapy, tissue engineering, and gene therapy have shown promise as potential treatments for EB. Stem cells capable of differentiating into skin cells, have demonstrated positive outcomes in preclinical and early clinical trials by promoting wound healing and reducing inflammation. Gene therapy, on the other hand, aims to correct the underlying genetic defects responsible for EB by introducing functional copies of mutated genes or modifying existing genes to restore protein function. Particularly for severe subtypes like Recessive Dystrophic Epidermolysis Bullosa (RDEB), gene therapy holds significant potential. This review aims to evaluate the role of new therapeutic approaches in the treatment of EB. The review includes findings from studies conducted on humans. While early studies and clinical trials have shown promising results, further research and trials are necessary to establish the safety and efficacy of these innovative approaches for EB treatment.
cell biology,medicine, research & experimental,cell & tissue engineering